NASDAQ:CDXS - Codexis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.17
  • Forecasted Upside: -1.21 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$32.56
▼ -1.72 (-5.02%)

This chart shows the closing price for CDXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Codexis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDXS

Analyst Price Target is $32.17
▼ -1.21% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Codexis in the last 3 months. The average price target is $32.17, with a high forecast of $38.00 and a low forecast of $29.00. The average price target represents a -1.21% upside from the last price of $32.56.

This chart shows the closing price for CDXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Codexis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2021HC WainwrightBoost Price TargetBuy$33.00 ➝ $38.00High
10/15/2021HC WainwrightBoost Price TargetBuy$28.00 ➝ $33.00Low
10/14/2021CowenBoost Price TargetOutperform$25.00 ➝ $32.00Low
10/1/2021Craig HallumReiterated RatingBuy$30.00Low
8/6/2021HC WainwrightBoost Price TargetBuy$27.00 ➝ $28.00Medium
8/6/2021Piper SandlerBoost Price TargetOverweight$32.00 ➝ $34.00High
6/18/2021Stifel NicolausReiterated RatingBuy$30.00High
6/18/2021HC WainwrightBoost Price TargetBuy$27.00High
4/12/2021Piper SandlerInitiated CoverageOverweight$32.00High
3/1/2021Stifel NicolausInitiated CoverageBuy$30.00Low
2/26/2021HC WainwrightBoost Price TargetBuy$21.00 ➝ $26.00High
12/30/2020BenchmarkBoost Price TargetBuy$21.00 ➝ $29.00N/A
8/7/2020HC WainwrightReiterated RatingBuy$21.00High
7/15/2020StephensInitiated CoverageOverweight$16.00High
5/11/2020HC WainwrightLower Price TargetBuy$22.50 ➝ $21.00High
3/10/2020BenchmarkInitiated CoverageBuyHigh
2/28/2020HC WainwrightReiterated RatingBuy$22.50High
12/24/2019HC WainwrightReiterated RatingBuy$22.50High
8/8/2019HC WainwrightReiterated RatingBuy$22.50Medium
3/4/2019HC WainwrightBoost Price TargetBuy$22.50High
2/27/2019Craig HallumBoost Price TargetBuy$20.00 ➝ $25.00Medium
1/17/2019First AnalysisUpgradeNeutral ➝ Outperform$12.00 ➝ $19.00High
1/15/2019Jefferies Financial GroupBoost Price TargetBuy$4.00 ➝ $20.00Medium
1/14/2019HC WainwrightReiterated RatingBuy$16.50High
12/10/2018StephensBoost Price TargetOverweight$16.00 ➝ $25.00Medium
11/12/2018HC WainwrightSet Price TargetBuy$17.00High
9/5/2018Craig HallumBoost Price TargetBuy$15.00 ➝ $20.00Medium
6/19/2018CowenInitiated CoverageOutperform$18.00Medium
5/16/2018StephensInitiated CoverageOverweight$16.00High
3/12/2018HC WainwrightSet Price TargetBuy$12.00High
11/21/2017HC WainwrightReiterated RatingBuy$8.50N/A
10/13/2017Jefferies Financial GroupBoost Price TargetBuy$9.00 ➝ $11.00N/A
10/13/2017HC WainwrightBoost Price TargetBuy ➝ Buy$8.00 ➝ $8.50N/A
10/2/2017Jefferies Financial GroupReiterated RatingBuy$8.00 ➝ $9.00Low
8/11/2017HC WainwrightSet Price TargetBuy$8.00High
5/31/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$8.00High
5/11/2017HC WainwrightSet Price TargetBuy$8.00High
3/13/2017HC WainwrightSet Price TargetBuy$8.00Low
1/26/2017First AnalysisDowngradeOverweight ➝ Equal Weight$5.50N/A
1/4/2017LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$6.25N/A
(Data available from 12/4/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2021
  • 7 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2021
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2021
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2021
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/4/2021
  • 4 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
12/4/2021

Current Sentiment

  • 4 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Codexis logo
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Read More

Today's Range

Now: $32.56
Low: $32.01
High: $35.18

50 Day Range

MA: $32.67
Low: $23.10
High: $41.78

52 Week Range

Now: $32.56
Low: $16.55
High: $42.01

Volume

1,026,477 shs

Average Volume

841,495 shs

Market Capitalization

$2.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Codexis?

The following Wall Street research analysts have issued reports on Codexis in the last year: Benchmark Co., Cowen Inc, Craig Hallum, HC Wainwright, Piper Sandler, Stifel Nicolaus, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CDXS.

What is the current price target for Codexis?

6 Wall Street analysts have set twelve-month price targets for Codexis in the last year. Their average twelve-month price target is $32.17, suggesting a possible downside of 1.2%. HC Wainwright has the highest price target set, predicting CDXS will reach $38.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $29.00 for Codexis in the next year.
View the latest price targets for CDXS.

What is the current consensus analyst rating for Codexis?

Codexis currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDXS will outperform the market and that investors should add to their positions of Codexis.
View the latest ratings for CDXS.

How do I contact Codexis' investor relations team?

Codexis' physical mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company's listed phone number is (650) 421-8100 and its investor relations email address is [email protected] The official website for Codexis is www.codexis.com.